Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2019-12-20

FDA Approved: OLMESARTAN MEDOXOMIL / AMLODIPINE BESYLATE / HYDROCHLOROTHIAZIDE — Supplemental Application (Par Health USA, LLC)

View source ↗

Summary

The FDA approved a supplemental application for Par Health USA’s generic fixed-dose combination tablet of olmesartan medoxomil, amlodipine besylate, and hydroch…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • OLMESARTAN MEDOXOMIL / AMLODIPINE BESYLATE / HYDROCHLOROTHIAZIDE (olmesartan medoxomil / amlodipine besylate / hydrochlorothiazide)

Snippet

SUPPL AP for OLMESARTAN MEDOXOMIL / AMLODIPINE BESYLATE / HYDROCHLOROTHIAZIDE (OLMESARTAN MEDOXOMIL / AMLODIPINE BESYLATE / HYDROCHLOROTHIAZIDE)